Document:

Exhibit 10.11

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #1 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case Nos: ***

 

    	 

    	 

    

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #1 TO:

EXCLUSIVE LICENSE FOR

***

 

UC Case Nos: ***

 

 

 

Effective June 15, 2002 (the “EFFECTIVE
DATE OF AMENDMENT #1”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address
is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at
the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620 (“REGENTS”) and KINEMED,
INC., a Delaware corporation having a principal place of business at EmeryStation North, 5980 Horton Street, Suite 470,
Emeryville, CA 94608-2012 (“LICENSEE”), agree as follows:

 

ARTICLE 1.1 (BACKGROUND) substitute
the following:

		1.1	REGENTS has an assignment of:

			***(collectively referred to as “INVENTION”), and REGENTS’ PATENT RIGHTS as defined
below, which are directed to the INVENTION.

 

ARTICLE 1.2 (BACKGROUND) substitute
the following:

		1.2	LICENSEE entered into a letter agreement on March 4, 1999 (together with extensions thereof)
with REGENTS (now terminated) for the purpose of evaluating that portion of the INVENTION referred to in Article 1.1 (a) and
(b) above, which granted LICENSEE an exclusive right to negotiate an option or exclusive license agreement to the
INVENTION. LICENSEE entered into a second letter agreement on March 6, 2002 with REGENTS (terminating on June 15, 2002)
for the purpose of evaluating that portion of the INVENTION referred to in Article 1.1 (c) through (j) above, which granted LICENSEE
an exclusive right to negotiate an option or exclusive license agreement to the INVENTION. The letter agreements cover the
LICENSEE’s commitment to reimburse REGENTS’ past and ongoing patent costs during the period of good-faith
negotiation for an option agreement or an exclusive license agreement. The exclusive license between LICENSEE and REGENTS,
which this document amends, was executed on March 26, 2001 and grants patent rights under U.C. Cases *** and *** as defined in
that license agreement and in Art. 1.1 (a) and (b), above. As consideration for the exclusive license, in 2001 LICENSEE paid
to REGENTS:

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	U.C. Case Nos.: ***	CONFIDENTIAL
	Exclusive license/Kinemed, Inc.	 

 

    	2

    	 

    

 

		a)	in the name of Shellwater & Co., *** shares of fully paid and non-assessable common stock
of KineMed (with a par value of $.001 per share at the time);

		b)	and to REGENTS’ employee (and inventor of U.C. Case numbers *** Dr. Hellerstein), ***
shares of fully paid and non-assessable common stock of KineMed (with a par value of $.001 per share at the time);

		c)	and *** in cash.

The additional consideration added to the
exclusive license agreement (through this Amendment #1 to the exclusive license) described in Article 5.1 (b) below, is to
be apportioned, equally among the eight cases that are added to the license through this amendment. The eight additional
cases are: U.C. Case Nos.: *** as described in Article 1.1(c) — (j), above.

 

ARTICLE 1.3 (BACKGROUND) substitute
the following:

1.3       For the purpose
of Regents’ evaluation of LICENSEE’s capabilities as a LICENSEE, LICENSEE provided REGENTS with an initial Commercialization
Plan and business strategy describing its commercialization strategy for the INVENTION prior to negotiations for the
Agreement and an updated Commercialization Plan on May 15, 2002.

 

ARTICLE 2.1 (DEFINITIONS) add the following:

(j)       All of
Regents’ United States patent applications filed under U.C. Case Numbers .: *** as described in Article 1.1
(c) through (j) above, and;

 

ARTICLE 5 (LICENSE ISSUE FEE) substitute
the following:

5.1(a)LICENSEE shall pay to REGENTS
a non-creditable, non-refundable license fee of ***, within *** days following the final execution of this Agreement. In addition,
LICENSEE shall, within *** days after the final execution of this Agreement, cause to be issued to REGENTS, through its
nominee, Shellwater & Co., and to REGENTS’ employee a total of *** shares of stock in KineMed, Inc., in
accordance with the Shareholder’s Agreement between REGENTS and LICENSEE dated February 16, 2001. As of the EFFECTIVE
DATE OF AMENDMENT #1, REGENTS acknowledges that LICENSEE has fully paid to REGENTS this fee in this Article 5.1 (a).

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	U.C. Case Nos.: ***	CONFIDENTIAL
	Exclusive license/Kinemed, Inc.	 

 

    	3

    	 

    

 

5.1(b)LICENSEE
shall also pay to REGENTS a non-creditable, non-refundable license fee of *** on or before *** and an additional
non-creditable, non-refundable license fee of *** on or before ***. In addition, LICENSEE shall, within *** days
after the final execution of this amendment #1 to the Agreement, cause to be issued to REGENTS, through its nominee,
Shellwater & Co. *** shares of common stock in KineMed, Inc., in accordance with the Shareholder’s Agreements between
REGENTS and LICENSEE dated February 16, 2001 and June 11, 2002.

5.1(c)For any of
the following U.C. Case Numbers: ***. as described in Article 2.1(j) and in .Article 1.1 (c) through (j) above, if the corresponding
patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number, LICENSEE shall
be entitled to a credit of *** toward its future royalty payments to REGENTS pursuant to Article 6.1.

5.2     The license
issue fees are non-refundable and not an advance against royalties.  The issuance of the above-referenced shares of stock
shall in effect be non-refundable and shall likewise not be deemed an advance against royalties.

 

ARTICLE 7.1 (d) and (e) (DUE DILIGENCE)
add the following:

 

(d) ***

 

(e) ***

 

ARTICLE 23 (NOTICES) substitute the
following:

23.1     All notices
under this Agreement will be deemed to have been fully given when done in writing and deposited in the United States mail,
registered or certified, and addressed as follows:

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	U.C. Case Nos.: ***	CONFIDENTIAL
	Exclusive license/Kinemed, Inc.	 

 

    	4

    	 

    

 

	To REGENTS:	Office of Technology Licensing
	 	2150 Shattuck Avenue, Suite 510
	 	Berkeley, CA 94720-1620
	 	Attn.: Director
	 	(UC Case Nos.: ***)
	 	 
	To LICENSEE:	KineMed, Inc.
	 	EmeryStation North
	 	5980 Horton Street, Suite 470
	 	Emeryville, CA 94608-2012
	 	Attn.: David Fineman, President and CEO
	 	 
	w/ copy to:	Mr. James E. Burden
	 	KineMed, Inc.
	 	Administrative Office
	 	One Maritime Plaza, 4th Floor
	 	San Francisco, CA 94111-3407
	 	Phone 415 421 0222
	 	Fax 415 433 2996.

 

Either party may change its address
upon written notice to the other party.

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 

 

	By:	/s/William A. Hoskins	 	By	/s/David M. Fineman
	 	William A. Hoskins	 	 	David M. Fineman
	 	Director	 	 	President & CEO
	 	Office of Technology Licensing	 	 	 

 

	Date	July 8, 2002	 	Date	June 23, 2002

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	U.C. Case Nos.: ***	CONFIDENTIAL
	Exclusive license/Kinemed, Inc.	 

 

    	5Exhibit 10.12

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #2 TO:

 

EXCLUSIVE LICENSE

 

BETWEEN

 

KINEMED INC.

 

AND

 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

 

FOR

 

***

 

UC Case Nos: ***

 

    	 

    	 

    

 

UNIVERSITY OF CALIFORNIA, BERKELEY

 

OFFICE OF TECHNOLOGY LICENSING

 

 

 

AMENDMENT #2 TO:

EXCLUSIVE LICENSE FOR

***

 

UC Case Nos: ***

 

 

 

Effective October 15, 2002 (the
“EFFECTIVE DATE OF AMENDMENT #2”), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose
legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of
Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620
(“REGENTS”) and KINEMED, INC., a Delaware corporation having a principal place of business at EmeryStation
North, 5980 Horton Street, Suite 470, Emeryville, CA 94608-2012 (“LICENSEE”), agree to amend that
certain Agreement between REGENTS and LICENSEE which bears an effective date of February 16, 2001 (as amended by
Amendment #1, said Amendment #1 bearing an effective date of June 15, 2002), as follows:

 

ARTICLE 1.1 (k) (BACKGROUND) add the
following:

 

1.1k) ***

 

1.1 1) ***

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #2	CONFIDENTIAL

 

    	 

    	 

    

 

ARTICLE 2.1(j) (DEFINITIONS) substitute
the following:

 

(j) All of
Regents’ United States patent applications filed under U.C. Case Numbers .: *** as described in Article 1.1 (c) through
(1) above, and;

 

ARTICLE 5.1(b) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(b) LICENSEE shall
also pay to REGENTS a non-creditable, non- refundable license fee of *** on or before *** and an additional non-creditable, non-refundable
license fee of *** on or before ***. In addition, LICENSEE shall, within *** days after the final execution of this amendment
#1 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to REGENTS’ employee(s)
a total of *** shares of common stock in KineMed, Inc., in accordance with the Shareholder’s Agreements between REGENTS
and LICENSEE dated February 16, 2001 and June 11, 2002. As of the EFFECTIVE DATE OF AMENDMENT #2, REGENTS acknowledges that
LICENSEE has fully paid to REGENTS ***and *** shares of common stock in KineMed, Inc. in accordance with this Article 5.1(b).

 

As consideration for the addition of
REGENTS’ case *** by way of this second amendment to the Agreement, LICENSEE shall also pay to REGENTS a
non-creditable, non-refundable fee of *** on or before *** and shall, within *** days after the final execution of
this amendment #2 to the Agreement, cause to be issued to REGENTS, through its nominee, Shellwater & Co., and to
REGENTS employee(s) a total of *** shares of common stock in KineMed, Inc., in accordance with the
Shareholder’s Agreements between REGENTS and LICENSEE attached hereto as Exhibit A.

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #2	CONFIDENTIAL

 

    	 

    	 

    

 

ARTICLE 5.1(c) (LICENSE ISSUE FEE) substitute
the following:

 

5.1(c) For any of
the following U.C. Case Numbers *** as described in Article 2.1(j) and in Article 1.1 (c) through (1) above, if the
corresponding patent application(s) have not resulted at least one VALID CLAIM, then for each such U.C. Case Number,
LICENSEE shall be entitled to a credit of *** toward its future royalty payments to REGENTS pursuant to Article 6.1.

 

All remaining terms and conditions of the
Agreement (as amended) remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement in duplicate originals by their duly authorized officers or representatives. ‘

 

	THE REGENTS OF THE	 	KINEMED, INC.
	UNIVERSITY OF CALIFORNIA	 	 
	 	 	 
	By	/s/ William A. Hoskins	 	By	/s/ David M. Fineman
	 	William A. Hoskins	 	 	David M. Fineman
	 	Director	 	 	President & CEO
	 	Office of Technology Licensing	 	 	 

 

	Date November 18, 2002	 	Date November 15, 2002

 

*** INDICATES MATERIAL THAT WAS OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	Amendment #2	CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]